Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 294Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Sarcoma 142Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 58Ovarian Neoplasms 51Triple Negative Breast Neoplasms 50Neoplasms 50Lymphoma, Mantle-Cell 48Multiple Myeloma 47Carcinoma, Hepatocellular 47Neuroblastoma 44Neoplasm Metastasis 42Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Recurrence 27Lymphoma, T-Cell, Peripheral 27Osteosarcoma 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Doxorubicin × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡